ADELAIDA LAMAS FERREIRO – Antibiotic – Best Researcher Award

Published on by Infectious

ADELAIDA LAMAS FERREIRO - Antibiotic - Best Researcher Award

HOSPITAL UNIVERSITARIO RAMÓN Y CAJAL. UNIVERSIDAD DE ALCALÁ. MADRID - Spain

AUTHOR PROFILE

GOOGLE SCHOLAR

INTRODUCTION TO A LIFETIME OF CARE 🌍

Dr. Adelaida Lamas stands as a remarkable figure in pediatric pulmonology, with an illustrious career centered on cystic fibrosis and the vital role of antibiotic therapies. Her clinical dedication has spanned more than two decades, particularly in respiratory medicine, where her expertise has reshaped the management of chronic infections in pediatric patients. She has led national efforts to refine antibiotic administration strategies in cystic fibrosis, directly influencing treatment protocols and patient outcomes. As the principal investigator at the Ramón y Cajal Institute for Health Research (IRYCIS), she spearheaded pioneering research in pulmonary microbiology, emphasizing the interplay between antibiotics and microbial resistance. Her advocacy for inhaled antibiotic therapies was instrumental in expanding access to life-prolonging treatments. From neonatology to intensive care, Dr. Lamas’s practice was always anchored in evidence-based medicine and ethical care. Her guidance as an expert with the Spanish Agency for Medicines and Health Products (AEMPS) further established her as a key voice in antibiotic evaluation and therapeutic positioning. Dr. Lamas’s work not only provided clinical clarity but also raised the standard of care across Europe. Through antibiotic-driven protocols, she has improved survival and quality of life for countless children. Her legacy begins here, with antibiotics at its heart.

EARLY ACADEMIC PURSUITS 📚

Adelaida Lamas’s journey into pediatric pulmonology and antibiotic therapeutics began with rigorous medical education at the Universidad de Valladolid, followed by her specialization at the Ramón y Cajal University Hospital. Her early academic focus was deeply rooted in pediatric respiratory pathophysiology, especially how antibiotics influence outcomes in cystic fibrosis and critical care. During her doctoral studies at the Universidad Autónoma de Madrid, her award-winning thesis examined sedation monitoring in critically ill children—a project intersecting with the timing and dosing of antibiotics in intensive care. Her early exposure to pediatric infectious disease units shaped her understanding of antibiotic resistance, prompting her to explore novel modes of delivery like aerosolized antibiotics for neonatal care. She also participated in cross-institutional training in Spain and the United States, further deepening her comprehension of global antibiotic stewardship. These foundational years fostered her lifelong commitment to evidence-based antibiotic applications. Recognizing the intricacies of microbiome-antibiotic interactions, she published early papers that addressed microbial colonization in children and the antibiotic responses in respiratory infections. Her training laid a powerful groundwork, allowing her to rise not just as a clinician, but as an antibiotic-conscious academic. This early pursuit set the tone for decades of innovation centered on children’s health and antibiotic optimization.

PROFESSIONAL ENDEAVORS 🏥

Dr. Adelaida Lamas’s professional career spans over 25 years, during which she served as a consultant pediatric pulmonologist at the Ramón y Cajal University Hospital. There, she became the national reference point for cystic fibrosis management and antibiotic strategy development. One of her hallmark contributions was leading the design and oversight of antibiotic protocols within Spain’s CF newborn screening programs. Her expertise expanded into bioethics and clinical decision-making, where she lectured extensively on the appropriate use of antibiotics in pediatric populations. As a member of multiple national and international ethics and clinical trial committees, she advocated for safe and timely antibiotic use in vulnerable children. She also evaluated pediatric antibiotics for the Spanish Agency for Medicines and Health Products (AEMPS), helping shape regulatory decisions. Through her work with the European clinical trials initiative (Conect4children), she contributed to global guidelines for pediatric antibiotic trials. Her involvement in therapeutic positioning reports for inhaled antibiotics like tobramycin and aztreonam further positioned her as a thought leader in this field. Her daily practice married compassion with precision, always anchored in responsible antibiotic use. Dr. Lamas not only advanced care but reshaped antibiotic discourse in pediatrics through decades of resolute clinical endeavor and scholarly service.

CONTRIBUTIONS AND RESEARCH FOCUS 🔬

Throughout her prolific research career, Dr. Adelaida Lamas has published over 35 high-impact studies that focus on the intersection of pulmonary infections and antibiotic effectiveness in children with cystic fibrosis. Her groundbreaking work explored biofilm dynamics and how early antibiotic intervention alters pathogen colonization in respiratory tracts. She led key studies on the inhaled use of aztreonam, tobramycin, and other novel antibiotics that redefined how recurrent Pseudomonas aeruginosa infections are managed in chronic respiratory diseases. With collaborators from top European institutions, she investigated antibiotic heterogeneity and its role in resistance modulation. A strong advocate for combining antibiotics with probiotics, Dr. Lamas contributed to integrative therapeutic models that reduced microbial imbalance in CF patients. Her work in metaproteomics and gut microbiota establishment further emphasized the systemic effects of prolonged antibiotic use, positioning her as a forerunner in microbiome-aware therapy. Her leadership in randomized controlled trials ensured the ethical and scientific rigor of new antibiotic formulations. Her team’s publications are now widely cited in CF and pediatric pulmonology literature, influencing clinical guidelines across Europe. In short, her research has consistently pushed forward the boundaries of antibiotic science, ensuring that every child treated today benefits from decades of careful, research-driven innovation.

ACCOLADES AND RECOGNITION 🏅

Dr. Adelaida Lamas’s exceptional contributions to pediatric pulmonology and antibiotic therapies have garnered widespread recognition across clinical, academic, and governmental institutions. In 2006, her doctoral thesis received Spain’s “Dra. Juana Román First Prize,” the highest national honor in pediatric research. Her continued leadership earned her a permanent seat at the Spanish Agency for Medicines and Health Products (AEMPS), where she advised on pediatric antibiotic approvals. As principal investigator of several national and European antibiotic-related trials, she secured funding from global pharmaceutical leaders including Gilead and AstraZeneca. These trials revolutionized how antibiotic inhalation therapies are evaluated and prescribed for cystic fibrosis patients. Her recognition extended internationally when she was appointed as a key expert in pediatric pulmonology for Conect4children (c4c), shaping pan-European guidelines on antibiotic use in pediatric trials. Her teaching excellence earned her appointments at the Universidad de Alcalá and the International University of La Rioja, where she taught ethics in the use of antibiotics. Her voice is respected in editorial boards and therapeutic committees, particularly those focused on antibiotic innovation. In every honor received, the thread of her dedication to safe and effective antibiotic use in children remains central. Recognition of her work reflects the enduring impact of her antibiotic-focused legacy.

IMPACT AND INFLUENCE 🌐

The influence of Dr. Adelaida Lamas extends beyond the boundaries of her hospital and even her country. Her work in optimizing antibiotic protocols for pediatric pulmonology has inspired health policy reforms and research innovations globally. As one of the earliest adopters of inhaled antibiotic therapies, she helped bring these strategies from niche practices into standard protocols for cystic fibrosis patients. Her lectures on antibiotic resistance, ethical stewardship, and individualized therapy have been delivered across Europe and Latin America, where her voice commands respect and attention. Dr. Lamas’s influence is evident in international registries and multi-center trials, where her research and clinical models have been replicated. She has contributed significantly to the Spanish Federation of Cystic Fibrosis, promoting antibiotic literacy among patients and caregivers. Under her guidance, new pediatric pulmonologists have emerged, many of whom now lead CF units inspired by her antibiotic-focused methodologies. Her role in ethics committees ensured that antibiotic trials respect both safety and urgency—setting a benchmark for pediatric medicine. Dr. Lamas continues to shape antibiotic narratives through advisory boards, regulatory commissions, and academic forums. Her broad impact lies in proving that antibiotics, when used judiciously, are not just drugs—they are lifelines forged through science and compassion.

LEGACY AND FUTURE CONTRIBUTIONS 🌱

As Dr. Adelaida Lamas transitions from her active clinical roles, her legacy in pediatric pulmonology and antibiotic stewardship continues to flourish. She has trained countless professionals who now carry her antibiotic philosophy into new generations of care. Her published works serve as cornerstone references in antibiotic-based CF management and are embedded in Spain’s national respiratory care protocols. Beyond academia and hospitals, her advocacy has reached families and patients directly, helping demystify antibiotic use and resistance. Her future impact will unfold through her ongoing doctoral advisement roles, where she continues to guide research in hypertonic saline, probiotics, and next-generation antibiotics. She is also shaping ethical standards for emerging pediatric trials involving biologics and gene therapies, where the antibiotic baseline remains critical for infection control. With a strong foundation in both research and humanistic care, Dr. Lamas’s voice will remain central in regulatory debates and academic dialogues. Her legacy is proof that when science, ethics, and heart converge—especially around something as vital as antibiotics—the result is transformative. Looking ahead, she aims to contribute further by writing, mentoring, and consulting, all while ensuring that antibiotics remain a tool of precision, protection, and possibility for the children of tomorrow.

NOTABLE PUBLICATION

  • Title: Impact of SARS-CoV-2 infection in patients with cystic fibrosis in Spain: Incidence and results of the national CF-COVID19-Spain survey
    Authors: P. Mondejar-Lopez, E. Quintana-Gallego, R.M. Giron-Moreno, et al.
    Journal: Respiratory Medicine, Vol. 170, Article 106062, 2020

  • Title: Insulin resistance, β-cell dysfunction and differences in curves of plasma glucose and insulin in the intermediate points of the standard glucose tolerance test in adults with cystic fibrosis
    Authors: M.C. Megías, O.G. Albarrán, P.G. Vasco, A.L. Ferreiro, L.M. Carro
    Journal: Endocrinología y Nutrición (English Edition), Vol. 62(2), Pages 91–99, 2015

  • Title: A comprehensive evaluation of omega-3 fatty acid supplementation in cystic fibrosis patients using lipidomics
    Authors: Ó. Pastor, P. Guzmán-Lafuente, J. Serna, M. Muñoz-Hernández, A.L. Neyra, et al.
    Journal: The Journal of Nutritional Biochemistry, Vol. 63, Pages 197–205, 2019

  • Title: Protocol for the diagnosis and follow up of patients with cystic fibrosis
    Author: S. Gartner
    Journal: Anales de Pediatría (Barcelona, Spain: 2003), Vol. 71(3), Pages 250–264, 2009

  • Title: Tolerance of two inhaled hypertonic saline solutions in patients with cystic fibrosis
    Authors: L.M. Carro, A.L. Ferreiro, M.R. de Valbuena Maiz, C.W. Struwing, G.G. Álvarez, et al.
    Journal: Medicina Clínica, Vol. 138(2), Pages 57–59, 2012

Bidyut Matubber – Antibiotic – Best Researcher Award

Published on by Infectious

Bidyut Matubber - Antibiotic - Best Researcher Award

Khulna Agricultural University - Bangladesh

AUTHOR PROFILE

GOOGLE SCHOLAR 

EARLY ACADEMIC PURSUITS 🎓

Dr. Bidyut Matubber’s academic foundation is deeply rooted in veterinary public health and food hygiene. He completed his Doctor of Veterinary Medicine (DVM) in 2017 from Patuakhali Science and Technology University, securing a commendable CGPA of 3.74. Demonstrating his passion for advanced learning, he pursued a Master of Veterinary Public Health and Food Hygiene with a major in Antimicrobial Resistance, graduating with a perfect CGPA of 4.00 in 2019. These formative years reflect a consistent commitment to academic excellence and laid the groundwork for his specialization in food microbiology. During his master's tenure, Dr. Matubber actively participated in hands-on research activities, including antibiogram studies and chromatographic analysis. His academic environment exposed him to a multidisciplinary research setting, fostering a deeper understanding of microbiological threats in food systems. This exposure played a pivotal role in shaping his career and interest in public health. With a solid base in microbiology, statistics, and biosafety, he was well-prepared to address complex public health concerns, particularly those linked to antimicrobial resistance. His early academic journey was not just a pursuit of degrees but a strategic investment toward a research-intensive future in veterinary science and food safety, setting the stage for his impactful contributions.

PROFESSIONAL ENDEAVORS 🧪

Dr. Bidyut Matubber’s professional career commenced with a focused approach toward academia and applied research. Since November 2020, he has been serving as an Assistant Professor in the Department of Microbiology and Public Health at Khulna Agricultural University. In this role, he spearheads research on antimicrobial resistance and chemical residues in food items such as meat and milk. His work extends to critical extension activities, strengthening collaboration between universities, research institutions, and livestock farmers. His contributions aim to bridge the gap between scientific discoveries and practical applications in food safety. Prior to this, Dr. Matubber held the position of Master Research Fellow at his alma mater, where he honed his research skills in statistical software such as SPSS and R. He has also undergone extensive training in laboratory biosafety, surveillance, foot-and-mouth disease investigation, and herd production management. These multidimensional experiences enrich his capacity as both a researcher and educator. Dr. Matubber is not confined to the laboratory; his outreach and on-ground surveys enable him to assess real-world challenges faced by food handlers and animal health workers. His professional endeavors reflect a dynamic balance between rigorous research and meaningful community engagement, ensuring relevance and impact in every project he undertakes.

RESEARCH CONTRIBUTIONS AND FOCUS 🔬

Dr. Bidyut Matubber’s research trajectory is anchored in the critical domains of antimicrobial resistance (AMR), food microbiology, and public health. His work scrutinizes the presence of antibiotic resistance and chemical residues in livestock products — particularly meat and milk — in southern Bangladesh. His findings have been published in several reputable national and international journals, reinforcing his reputation as a dedicated scientific voice in the food safety sector. Notably, his recent studies explore the microbial contamination of street foods and the prevalence of multidrug-resistant pathogens in urban meat markets. These investigations have significant implications for public health, especially in developing countries grappling with poor food hygiene infrastructure. Dr. Matubber is also a contributing author in interdisciplinary topics, ranging from student mental health during online learning to reproductive issues in livestock. His collaborative research style has earned him co-authorship with international scholars and local experts, highlighting the diverse scope of his academic inquiries. Moreover, his work on biofilm resistance in farm industries and the evaluation of organic acid alternatives to antibiotic growth promoters reflect his forward-thinking approach. Altogether, his research contributions aim not just to describe problems but to offer actionable, evidence-based solutions in public health microbiology.

AWARDS AND RECOGNITION 🏆

Dr. Bidyut Matubber’s exemplary contributions to veterinary public health and food microbiology have been widely acknowledged through prestigious accolades. He was awarded the NST Research Fellowship (2019) by the Ministry of Science and Technology, Bangladesh — a competitive grant that recognized his potential in the field of antimicrobial resistance. In 2020, he won the Best Poster Presentation Award at the 3rd Annual Scientific Conference organized by the Coastal Vet Society of Bangladesh, showcasing his ability to communicate research effectively to scientific audiences. Further acknowledging his innovation and commitment, the Ministry of Science and Technology honored him with the Technology Invention, Research, and Development Project (R&D) grants in both 2021 and 2022. Perhaps most significantly, he received the Best Researcher Award (2022) from the Khulna Agricultural University Teacher’s Association for his outstanding scholarly accomplishments. These accolades are not just ceremonial; they are powerful affirmations of Dr. Matubber’s enduring influence in microbiology and public health research. They reflect his relentless pursuit of scientific excellence, impactful community engagement, and forward-looking research that addresses urgent food safety challenges in Bangladesh. Each award underlines a milestone in his evolving career, cementing his place as a key thought leader in his domain.

IMPACT AND INFLUENCE 🌍

Dr. Matubber's research has far-reaching implications for public health policy and food safety in Bangladesh. His work on antimicrobial resistance in meat and milk serves as a wake-up call for food safety regulators and veterinary policymakers. By highlighting the presence of drug-resistant bacteria in widely consumed animal products, his studies provide a critical evidence base for shaping food inspection protocols and public awareness campaigns. Beyond his published findings, Dr. Matubber plays a pivotal role in academic and field-level training, educating young researchers and practitioners about biosafety, food hygiene, and AMR surveillance. His influence also extends into interdisciplinary domains, as seen in his co-authored work on student anxiety during e-learning and reproductive health in livestock. Dr. Matubber's ability to synthesize data into policy-relevant recommendations amplifies his impact beyond academia. As a faculty member, he actively mentors future scientists and contributes to the university's knowledge-sharing platforms. His integrated approach — combining lab research, fieldwork, teaching, and publication — creates a ripple effect of influence across public health, education, and rural livelihoods. Through conferences, training programs, and collaborative networks, Dr. Matubber continues to shape not only scientific discourse but also the operational realities of food safety and veterinary health in Bangladesh.

LEGACY AND FUTURE CONTRIBUTIONS 🔭

Dr. Bidyut Matubber’s academic journey and professional milestones lay the foundation for a legacy marked by scientific integrity, community relevance, and transformative impact. Looking ahead, he is poised to expand his research into broader themes like the environmental reservoirs of antimicrobial resistance, molecular epidemiology, and climate-linked zoonotic diseases. His ongoing projects involving the contamination levels in street food and multidrug-resistant pathogens in meats are likely to evolve into larger surveillance frameworks with regional or national scope. Moreover, Dr. Matubber envisions integrating genomic tools and AI-driven analytics into his research to better understand resistance mechanisms. As a faculty member, he aims to establish a specialized research hub within Khulna Agricultural University that focuses on foodborne pathogens and antibiotic resistance. His long-term goals include mentoring doctoral candidates and fostering international research collaborations, particularly in South Asia and Southeast Asia. With his background in both laboratory and field-based research, Dr. Matubber is ideally positioned to contribute to global initiatives like the WHO's One Health framework. His legacy will not only be defined by his publications or awards, but by the structural improvements he brings to food safety systems, academic training, and public health policies in Bangladesh and beyond.

SUMMARY OF ACHIEVEMENTS 🧾

Dr. Bidyut Matubber is a dynamic academic, microbiologist, and public health researcher based at Khulna Agricultural University. With over five years of expertise in food microbiology and antimicrobial resistance, his work has led to impactful research on contamination in meat, milk, and street foods across southern Bangladesh. He has co-authored numerous papers in reputed journals, participated in national training programs, and successfully acquired competitive grants. His professional tenure includes key roles as an Assistant Professor and Master Research Fellow, underscoring a consistent trajectory of growth. Recognized for both scientific innovation and practical relevance, he has received prestigious awards, including the NST Research Fellowship and the Best Researcher Award by his university. His research has informed public policy and raised awareness about food safety issues in underserved communities. By combining rigorous lab work, strategic field outreach, and teaching excellence, Dr. Matubber exemplifies a researcher whose work transcends academia to affect real-world change. His story is one of perseverance, interdisciplinary collaboration, and a passionate commitment to improving health outcomes through science.

NOTABLE PUBLICATION

  • Title: Anxiety and its determinants among undergraduate students during E-learning in Bangladesh amid COVID-19
    Authors: MN Hoque, A Hannan, S Imran, MA Alam, B Matubber, SM Saha
    Journal: Journal of Affective Disorders Reports, Volume 6, Article 100241, 2021

 

  • Title: Factors associated with food safety knowledge and practices among meat handlers in Bangladesh: a cross-sectional study
    Authors: MH Al Banna, TR Disu, S Kundu, BO Ahinkorah, K Brazendale, AA Seidu, ...
    Journal: Environmental Health and Preventive Medicine, Volume 26, Article 84, 2021

 

  • Title: Pernicious attitude of microbial biofilms in agri-farm industries: Acquisitions and challenges of existing antibiofilm approaches
    Authors: SH Toushik, A Roy, M Alam, UH Rahman, NK Nath, S Nahar, B Matubber, ...
    Journal: Microorganisms, Volume 10, Issue 12, Article 2348, 2022

 

  • Title: Evaluation of different parameters in relation to repeat breeding of cows at the coastal areas of Bangladesh
    Authors: B Matubber, AK Paul, S Das
    Journal: Research in Agriculture Livestock and Fisheries, Volume 5, Issue 1, Pages 49–55, 2018

 

  • Title: Antibiotic resistance and residue in chicken, cattle, buffalo and goat meats in different southern districts of Bangladesh
    Authors: B Matubber, FI Rume, MEH Kayesh, MM Rahman, MR Amin, MA Asgar, ...
    Journal: Asian-Australasian Journal of Food Safety and Security, Volume 5, Issue 1, Pages 19–26, 2021

Charlene Pillay – Antibiotic – Best Researcher Award

Published on by Infectious

Charlene Pillay - Antibiotic - Best Researcher Award

Durban University of Technology - South Africa 

AUTHOR PROFILE

ORCID

🎓 EARLY ACADEMIC PURSUITS

Dr. Charlene Pillay’s academic journey began at the University of KwaZulu-Natal, where she pursued a passion for microbiology, culminating in a PhD in 2012. Her doctoral thesis focused on microbiologically influenced corrosion—an intersection of microbiology and material science—under the guidance of Professor Johnson Lin. This work explored the impact of nitrate sources on steel corrosion in simulated systems, laying a strong foundation for her future research interests. She earlier completed her MSc, BSc Honours, and BSc in Microbiology at the same institution. These academic milestones not only reflect her dedication but also shaped her into a specialist with deep-rooted scientific curiosity. Her early academic accomplishments were punctuated by significant research, blending microbiology with environmental and industrial applications. This robust educational background has since served as the bedrock of her teaching and research endeavors. Driven by curiosity and scholarly discipline, Dr. Pillay’s academic formation set the tone for a prolific scientific career.

👩‍🔬 PROFESSIONAL ENDEAVORS IN EDUCATION

Currently serving as a Senior Lecturer at Durban University of Technology (DUT), Dr. Charlene Pillay is deeply engaged in academic mentorship, curriculum development, and student supervision. Since 2015, she has delivered lectures, coordinated work-integrated learning, and facilitated essential industry-academic linkages. Her role extends beyond the classroom, involving the academic supervision of students placed in industrial settings, thus reinforcing experiential learning. Before joining DUT, she held various teaching and technical positions at the University of KwaZulu-Natal, including AdHoc Lecturer roles in Bacteriology and Advanced Bacteriology, and a stint as Laboratory Technician. These roles helped her develop both instructional expertise and technical skills crucial in laboratory education. Her teaching philosophy blends theory with hands-on experience, equipping students with a holistic understanding of microbiology. Through her academic contributions, she has established herself as a dynamic educator committed to nurturing future scientists and bridging academia with real-world applications in biosciences.

🧪 CONTRIBUTIONS AND RESEARCH FOCUS

Dr. Pillay’s research focus reflects a unique synergy between microbiology, corrosion science, and ethnopharmacology. Initially concentrated on microbiologically influenced corrosion, her scholarly journey evolved to include antimicrobial research, bioremediation, and computational drug discovery using traditional medicinal plants. She has supervised numerous Honours and Master’s research projects addressing diverse topics such as bacterial modulation, type 2 diabetes therapy, soil bioremediation, and plant-based antimicrobial agents. Her publication portfolio spans high-impact journals like Archives of Microbiology, BMC Genomics, and Metabolites, showcasing work on quorum sensing modulators, gut microbiome studies, and therapeutic validation of plant-derived compounds. Notably, her interdisciplinary investigations bridge computational modeling with in vitro validations. Dr. Pillay’s research significantly contributes to understanding microbial behavior, the utility of plant secondary metabolites in health, and sustainable biomedical solutions. Her work remains rooted in addressing real-world health challenges through science-driven innovation, positioning her as a leading voice in applied microbiological research.

🏆 ACCOLADES AND RECOGNITION

Dr. Charlene Pillay’s scholarly excellence has earned her multiple accolades that underscore her research impact and scientific promise. She received the prestigious Ivan Oligvie Award from the Corrosion Institute of Southern Africa in 2008 for her early work in corrosion science. In 2009, she was honored with the SASM-Bio2Biz Travel Award, followed by a local conference travel award from the Faculty of Science and Agriculture at UKZN in 2011. These recognitions mark pivotal moments in her career, affirming the quality and relevance of her research. Beyond formal awards, her consistent publication record in reputable scientific outlets and active participation in interdisciplinary research teams further validate her professional standing. Through her collaborative work with colleagues like Professors Sabiu and Lin, Dr. Pillay continues to earn respect in both academic and applied science spheres. Her accolades reflect not only academic merit but also her growing influence as a respected contributor in microbiological and biomedical sciences.

🌿 IMPACT THROUGH SCIENTIFIC INNOVATION

Dr. Pillay's research has profound implications for environmental sustainability and public health, particularly through her investigations into plant-based therapeutics and microbial ecology. By integrating traditional medicinal knowledge with modern cheminformatics, she contributes to the discovery of bioactive compounds with the potential to combat non-communicable diseases like diabetes. Her studies on plant secondary metabolites, such as flavonoids and phenolic acids, are pivotal in developing alternative therapeutic strategies. Likewise, her research into bacterial biofilms and quorum sensing provides critical insights into managing antimicrobial resistance. The environmental aspect of her work—focusing on biodegradation of contaminants and soil microbiome dynamics—highlights her commitment to ecological well-being. These innovative approaches not only advance scientific understanding but also propose sustainable, low-cost healthcare and environmental solutions. Her work inspires future scientists to pursue research with tangible societal benefits, thereby enhancing her broader impact across academic, medical, and ecological domains.

👥 MENTORSHIP AND SCHOLARLY INFLUENCE

As a postgraduate supervisor, Dr. Charlene Pillay has significantly shaped the next generation of microbiologists and biomedical researchers. Her mentorship extends to BTech, Honours, and Master's students, with projects spanning from bioremediation techniques to computational drug modeling. She is known for encouraging innovation and critical thinking, guiding students through complex scientific methods and interdisciplinary topics. Many of her mentees have focused on real-world challenges such as antimicrobial resistance, plant-based drug development, and gut microbiome studies. Her mentorship fosters independence and scientific rigor, qualities evident in the student theses she has overseen. Through these scholarly interactions, she cultivates a research culture grounded in curiosity, integrity, and relevance. Her influence extends beyond academia into healthcare and biotechnology industries via her well-trained graduates. This legacy of mentorship underscores her dual role as both educator and enabler, investing in people as passionately as she invests in scientific exploration.

🔮 LEGACY AND FUTURE CONTRIBUTIONS

Dr. Charlene Pillay envisions a legacy rooted in transformative science and inclusive education. Her ambition to become a full professor with a thriving cohort of successful postgraduates reflects her long-term dedication to academic leadership. With aspirations to secure major research funding, she aims to expand her work in ethnopharmacology and microbial pathogenesis, focusing on groundbreaking, plant-based interventions for global health challenges. Her evolving research portfolio suggests forthcoming contributions in personalized medicine, antimicrobial strategies, and microbial genomics. As a thought leader in integrating traditional knowledge with modern science, she continues to set new standards for interdisciplinary research. Dr. Pillay’s legacy is one of innovation, mentorship, and impact—building bridges between past wisdom and future science. Her future contributions are poised to influence not only academia but also public health policy, environmental management, and scientific education, making her a pivotal figure in the global scientific community.

NOTABLE PUBLICATION

Title: A metagenomic investigation of the faecal RNA virome structure of asymptomatic chickens obtained from a commercial farm in Durban, KwaZulu-Natal province, South Africa
Authors: Nwokorogu, Vivian C.; Pillai, Santhosh; San, James E.; Pillay, Charlene; Nyaga, Martin M.; Sabiu, Saheed
Journal: BMC Genomics (2024)

Title: Cheminformatics Identification and Validation of Dipeptidyl Peptidase-IV Modulators from Shikimate Pathway-Derived Phenolic Acids towards Interventive Type-2 Diabetes Therapy
Authors: Balogun, Fatai Oladunni; Naidoo, Kaylene; Aribisala, Jamiu Olaseni; Pillay, Charlene; Sabiu, Saheed
Journal: Metabolites (2022)

Title: Identification of Flavonoid C-Glycosides as Promising Antidiabetics Targeting Protein Tyrosine Phosphatase 1B
Authors: Rampadarath, Athika; Balogun, Fatai Oladunni; Pillay, Charlene; Sabiu, Saheed
Journal: Journal of Diabetes Research (2022)

Title: Poultry gut health - microbiome functions, environmental impacts, microbiome engineering and advancements in characterization technologies
Authors: Aruwa, Christiana Eleojo; Pillay, Charlene; Nyaga, Martin M.; Sabiu, Saheed
Journal: Journal of Animal Science and Biotechnology (2021)

Title: The impact of additional nitrates in mild steel corrosion in a seawater/sediment system
Authors: Pillay, Charlene; Lin, Johnson
Journal: Corrosion Science (2014)

Somdeb Bose Dasgupta – Microbial Pathogenesis and Virulence – Best Researcher Award

Published on by Infectious

Somdeb Bose Dasgupta - Microbial Pathogenesis and Virulence - Best Researcher Award

IIT Kharagpur - India

AUTHOR PROFILE 

SCOPUS

EARLY ACADEMIC PURSUITS 🎓

Dr. Somdeb Bose Dasgupta began his scientific journey with a B.Sc in Physiology, Chemistry, and Zoology from City College, University of Calcutta, graduating with first-class honors in 2001. He pursued an M.Sc in Biophysics & Molecular Biology from Rajabazar Science College, University of Calcutta, and again secured first-class distinction. His academic rigor culminated in a Ph.D. in Molecular Parasitology from CSIR-IICB and Jadavpur University in 2009, where he was awarded the Best Thesis Award. During his doctoral years, Dr. Dasgupta delved deep into the molecular machinery of parasitic organisms, setting the foundation for a career that would be defined by his dedication to host-pathogen interactions. The exceptional clarity and originality of his doctoral research earned him early recognition in India’s scientific community, establishing a trajectory toward pioneering work in infectious diseases and immunology, especially concerning neglected tropical diseases like Leishmaniasis and Tuberculosis.

PROFESSIONAL ODYSSEY 🌍

Following his doctorate, Dr. Dasgupta expanded his scientific horizon through a postdoctoral fellowship at the University of Basel’s Biozentrum in Switzerland, from 2009 to 2014, where he worked on macrophage-pathogen interactions. This global exposure refined his research methodologies and enriched his understanding of molecular immunology. He then returned to India to contribute as an Assistant Professor at IIT (BHU) Varanasi from 2014 to 2016, before joining IIT Kharagpur in the Department of Biotechnology in 2016. At IIT Kharagpur, he rose to the position of Assistant Professor Grade I and became a pivotal figure in both undergraduate and postgraduate teaching. His courses span Molecular Biology, Neurophysiology, Biochemistry, and Bioprocess Engineering, nurturing the next generation of biotechnologists. His professional odyssey reflects a balance between international research excellence and a deep-rooted commitment to Indian scientific development. Throughout, he has maintained a clear vision: to translate basic science into therapeutic and diagnostic breakthroughs against life-threatening infectious diseases.

RESEARCH FOCUS 🔬

Dr. Dasgupta’s research lies at the intersection of molecular immunology, cellular microbiology, and genome editing. His lab investigates host-pathogen dynamics, especially in Mycobacterium tuberculosis and Leishmania donovani infections—diseases of critical importance to the Indian subcontinent. Utilizing CRISPR/Cas9 technologies, his team uncovers how host enzymes, particularly kinases and phosphatases, are manipulated by pathogens to ensure survival. His group is innovating host-directed therapeutics to bypass drug resistance by reactivating immune responses and restoring macrophage functionality. His approach includes drug repurposing strategies—like testing tricyclic antidepressants for anti-leishmanial use—and developing novel diagnostics for drug-resistant TB. Additionally, Dr. Dasgupta studies how parasitic infections influence phagosome maturation and immune modulation. His projects explore everything from biochemical pathway elucidation to advanced nanocarrier-based drug delivery systems. By combining cellular, biochemical, and genomic strategies, his lab offers crucial insights into both fundamental disease biology and translational medicine, with the aim of improving public health outcomes across endemic regions.

PIONEERING CONTRIBUTIONS 🧪

Over his career, Dr. Dasgupta has contributed over 38 research articles, five book chapters, and 25 conference proceedings, with many featured in high-impact journals like PNAS, FEBS Journal, and PLOS Pathogens. His pioneering findings—such as the discovery of how S-nitrosylation of mycobacterial Protein Kinase G (PknG) aids pathogen survival—have received global attention, including journal cover highlights and editor’s choice selections. At the forefront of translational research, he developed groundbreaking assays to study host-pathogen phospho-signaling, designed nanocarrier systems for immunomodulatory drug delivery, and repurposed common drugs into potential antiparasitic treatments. His innovations in CRISPR-based gene editing of host and pathogen genomes have redefined therapeutic targets. Further, his role in establishing India’s hybrid BSL-III facility at IIT Kharagpur has paved the way for safe, cutting-edge research on high-risk pathogens. Collectively, Dr. Dasgupta’s work bridges discovery and application, positioning him as a vanguard of molecular parasitology and infectious disease biology.

AWARDS AND RECOGNITION 🏅

Dr. Dasgupta’s scholarly excellence has been widely acknowledged. He was honored with the prestigious INSA Young Scientist Award in 2011 for contributions to biophysics and biochemistry, followed by the coveted DBT-Ramalingaswamy Fellowship in 2015. His postdoctoral research earned him the EMBO Long Term Fellowship in 2009, reflecting international acclaim. He has received multiple Best Poster Awards at national and international symposia, including the Annual Post-doc Retreats in Switzerland and the National Congress of Parasitology in India. His publications have been featured on journal covers and spotlighted for editorial distinction. He also received a DBT-CTEP Travel Award to attend the World Congress in Infectious Diseases in London, showcasing his global scientific presence. These accolades underscore both the depth and societal impact of his research. Through sustained excellence in discovery, innovation, and mentorship, Dr. Dasgupta has become a beacon in the field of molecular microbiology and immunopathology, inspiring peers and proteges alike.

IMPACT AND INFLUENCE 🌐

Dr. Dasgupta’s influence extends beyond laboratory research into public health, diagnostics, and therapeutic development. His contributions are instrumental in tackling antimicrobial resistance—one of modern medicine’s gravest challenges. By advancing host-directed therapies and creating rapid point-of-care diagnostic tools, he directly impacts clinical strategies for TB and Leishmaniasis. His leadership in major government-funded projects—ranging from ICMR, DST, DBT, to SERB—demonstrates trust in his ability to deliver translational outcomes. His work has informed national health priorities and contributed to India’s strategic push toward self-reliance in infectious disease control. As a mentor and educator, he shapes future scientists, embedding translational thinking in their academic DNA. His integrated approach, which combines molecular biology, nanotechnology, and immunology, sets a benchmark for interdisciplinary biomedical research in India. Through his visionary projects and collaborations, Dr. Dasgupta is not only solving today's biomedical problems but also laying the groundwork for long-term scientific resilience and healthcare innovation.

LEGACY AND FUTURE HORIZONS 🚀

Dr. Dasgupta’s legacy lies in transforming how we understand and combat chronic infectious diseases in resource-limited settings. His work champions a paradigm shift—from pathogen-centric drug design to host-targeted intervention, which offers sustainable solutions in the face of evolving drug resistance. The upcoming years promise even greater impact: his team is pioneering biosensors for non-invasive TB detection and leveraging liposomal drug delivery platforms for improved efficacy. With multiple ICMR-backed projects underway, including ENLIGHTEN—a non-invasive latent TB detection initiative—Dr. Dasgupta continues to chart untraveled paths in diagnostic science. He also plays a central role in shaping high-containment laboratory infrastructure to safely study dangerous pathogens. His foresight, collaborative spirit, and relentless pursuit of translational relevance ensure that his contributions will endure in both academic and clinical domains. Dr. Somdeb Bose Dasgupta is poised to remain a cornerstone of biomedical innovation, where his science continues to illuminate pathways toward global health equity.

NOTABLE PUBLICATION 

 Article Title:
Resolving the polycistronic aftermath: Essential role of topoisomerase IA in preventing R-loops in Leishmania
Authors: P. Das, A. Hazra, S. Saha, H.K. Majumdar, S. BoseDasgupta
Journal: The Journal of Biological Chemistry, 2024

 Article Title:
Gelatin-decorated Graphene oxide: A nanocarrier for delivering pH-responsive drug for improving therapeutic efficacy against atherosclerotic plaque
Authors: S.K. Yadav, S. Das, A. Lincon, S.K. Ray, S.C. Das
Journal: International Journal of Pharmaceutics, 2024